Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supreme Court Gives Some Relief, But Leaves Open Questions For Dx Patents

This article was originally published in The Gray Sheet

Executive Summary

Diagnostics and biotech firms praised a June 28 Supreme Court opinion for allowing judges some flexibility in ruling on the patent-eligibility of "process" claims, but patent attorneys warn that many issues remain unsettled

You may also be interested in...



'Alice' In Patent Land: Finding Patentable Digital Health Innovations Is No Easy Task

While the mobile health sector and digital health in general is poised for a major boom, a 2014 case, Alice Corp. v. CLS Bank International, continues to be a major hurdle for manufacturers wanting to patent their software. While there are some recent positive trends, attorneys recommend caution and proactive steps to make the best of the current patent environment.

Myriad Gets Mixed Decision in Supreme Court; Biotech Industry Fears Fallout

Supreme Court unanimously holds that DNA isolated from the human body cannot be patented but cDNA, which is created in a laboratory, can be.

Is That A Diagnostic Method Patent Or A Law Of Nature? Supreme Court Hears Arguments

A case argued before the Supreme Court Dec. 7 offers the justices an opportunity to place stricter limits on the types of claims that diagnostic makers can latch onto for patent protection. But while the justices had many questions on appropriate standards for patent eligibility, few clear answers surfaced.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

MT029097

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel